LGALS1 and neoplasm: [29,30] Additionally, the overexpression of β-galactoside binding lectins (galectins 1/3/9) by several tumors (e.g. melanoma, Hodgkin’s lymphoma, pancreatic carcinoma, and neuroblastoma) may facilitate tumor immune evasion and modulate anti-tumour immune responses.